

CITATION REPORT

List of articles citing

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data

DOI: 10.1016/j.pharmthera.2014.07.001

Pharmacology & Therapeutics, 2015, 145, 43-57.

Source: <https://exaly.com/paper-pdf/62900101/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
353	Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. <i>Journal of Psychopharmacology</i> , 2014 , 28, 891-902	4.6	71
352	Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT ₃ receptors enhances release of serotonin, norepinephrine, and acetylcholine. 2015 , 20, 455-9		14
351	Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. 2015 , 20, 515-9		13
350	Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. 2015 , 20, 331-6		16
349	Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition. <i>Current Topics in Behavioral Neurosciences</i> , 2016 , 28, 475-97	3.4	2
348	Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. 2015 , 11, 1193-212		13
347	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. 2015 , 95, 81-97		145
346	Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT _{2A} and 5-HT _{2C} receptor ligands. 2015 , 25, 1427-30		18
345	Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine. 2015 , 6, 970-86		72
344	The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. 2015 , 37, 2309-2323.e6		13
343	Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. <i>Journal of Psychopharmacology</i> , 2015 , 29, 1092-105	4.6	13
342	Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. 2015 , 12, 2036-48		62
341	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. 2015 , 49, 1087-206		461
340	Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. 2015 , 25, 599-656		86
339	A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. 2015 , 40, 2025-37		193
338	A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. 2015 , 232, 2061-70		66
337	NLX-112, a novel 5-HT _{1A} receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. 2015 , 271, 335-50		51

336	Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. 2015 , 14, 1291-304			36
335	Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. 2015 , 20, 1142-50			80
334	60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress. 2015 , 25, 591-8			13
333	Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?. 2015 , 23, 210-3			5
332	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. 2015 , 64, 88-98			39
331	Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. 2015 , 6, 1892-900			19
330	The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. 2015 , 4, 301-311			2
329	Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. <i>Journal of Psychopharmacology</i> , 2015 , 29, 1085-91	4.6		17
328	Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma. 2015 , 7, 2881-94			17
327	Antidepressant Drugs. 2016 , 38, 11-19			
326	[Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence]. 2016 , 144, 1326-1335			4
325	Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. 2016 , 10, 541			35
324	Synthesis and Structure-Activity Relationship Analysis of 5-HT ₁ Receptor Antagonists: Piperazin-1-yl Substituted Unfused Heterobiaryls. 2016 , 21, 433			3
323	Vortioxetin ¿ein neues Antidepressivum?. 2016 , 27, 34-37			
322	The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 523-31	3.1		5
321	Hippocampal 5-HT ₇ receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo. 2016 , 173, 1438-51			15
320	Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. 2016 , 21, 162-83			26
319	What role for vortioxetine?. 2016 , 54, 30-3			0

318	Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine. 2016 , 63, 25-28		
317	The Discovery of the Antidepressant Vortioxetine and the Research that Uncovered Its Potential to Treat the Cognitive Dysfunction Associated with Depression. 2016 , 189-214		1
316	Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed Rats. 2017 , 20, 316-323		8
315	Review of a New Multimodal Antidepressant Vortioxetine. 2016 , 16, 44-48		1
314	Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. 2016 , 233, 2813-25		47
313	Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000). <i>Journal of Psychopharmacology</i> , 2016 , 30, 1129-1136	4.6	3
312	Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. 2016 , 21, 143-61		73
311	Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. 2016 , 55, 1115-27		13
310	Involvement of 5-HT ₃ receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission. 2016 , 108, 73-81		46
309	Antidepressants. 2016 , 205-245		
308	The serotonergic system and cognitive function. 2016 , 7, 35-49		101
307	Effects of citalopram on jaw-closing muscle activity during sleep and wakefulness in mice. 2016 , 113, 48-55		3
306	Expression of Serotonin _{2C} Receptors in Pyramidal and GABAergic Neurons of Rat Prefrontal Cortex: A Comparison with Striatum. 2017 , 27, 3125-3139		16
305	The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. 2016 , 11, 969-81		6
304	Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. 2016 , 358, 472-82		17
303	Sexual Dysfunction Due to Psychotropic Medications. 2016 , 39, 427-63		36
302	Structures and physicochemical properties of vortioxetine salts. 2016 , 72, 723-732		7
301	The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. <i>Journal of Psychopharmacology</i> , 2016 , 30, 1099-1128	4.6	24

300	Vortioxetine: A Review in Cognitive Dysfunction in Depression. 2016 , 76, 1675-1682		44
299	A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. 2016 , 233, 3259-67		22
298	¿En qué consiste el efecto procognitivo de los antidepresivos?. 2016 , 23, 34-39		
297	Future Strategies for the Treatment of Depression. 2016 , 557-571		1
296	Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review. 2016 , 71, 27-38		34
295	An Investigation Into Vortioxetine Salts: Crystal Structure, Thermal Stability, and Solubilization. 2016 , 105, 2123-8		7
294	A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. 2016 , 786, 29-35		19
293	Herbal Medicine in Depression. 2016 ,		3
292	Traditional and Novel Possible Targets for Antidepressant Drugs. 2016 , 43-73		1
291	The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. 2016 , 19,		104
290	Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. 2016 , 103, 143-54		16
289	Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. 2016 , 68, 25-30		6
288	The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. <i>Journal of Psychopharmacology</i> , 2016 , 30, 242-52	4.6	81
287	Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. 2016 , 141, 28-41		14
286	5HT3 receptors: Target for new antidepressant drugs. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 64, 311-25	9	27
285	Vortioxetine: a New Treatment for Major Depressive Disorder. 2016 , 17, 421-31		43
284	Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus. 2016 , 26, 234-245		27
283	[Vortioxetine: a new antidepressant to treat depressive episodes]. 2016 , 42, 48-58		1

282	Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. 2016 , 190, 357-361		4
281	The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. <i>Journal of Psychopharmacology</i> , 2016 , 30, 13-22	4.6	84
280	Protein biomarkers of mood disorders. 2017 , 30, 7-12		3
279	Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. 2017 , 69, 595-601		38
278	A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: Possible roles of direct receptor modulation. 2017 , 121, 89-99		8
277	Response of Htr3a knockout mice to antidepressant treatment and chronic stress. 2017 , 174, 2471-2483		15
276	Z-Guggulsterone Produces Antidepressant-Like Effects in Mice through Activation of the BDNF Signaling Pathway. 2017 , 20, 485-497		24
275	Harmine produces antidepressant-like effects via restoration of astrocytic functions. 2017 , 79, 258-267		30
274	Acute dosing of vortioxetine strengthens event-related brain activity associated with engagement of attention and cognitive functioning in rats. 2017 , 1664, 37-47		5
273	Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery. 2017 , 8, 932-942		48
272	New Trends in Antidepressant Drug Research. 2017 , 21-52		
271	The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. 2017 , 7, e00622		13
270	Crystal Structures, X-Ray Photoelectron Spectroscopy, Thermodynamic Stabilities, and Improved Solubilities of 2-Hydrochloride Salts of Vortioxetine. 2017 , 106, 1069-1074		4
269	Crassifoside H improve the depressive-like behavior of rats under chronic unpredictable mild stress: Possible involved mechanisms. 2017 , 135, 77-84		14
268	Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT receptor in the treatment of major depressive disorder. 2017 , 19, 28885-28896		31
267	Drug repurposing may generate novel approaches to treating depression. 2017 , 69, 1428-1436		18
266	Class A GPCR: Serotonin Receptors. 2017 , 129-172		
265	Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats. 2017 , 79, 499-502		1

264	Developing Serotonergic Antidepressants Acting on More Than the Serotonin Transporter. 2017 , 335-367		
263	Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. 2017 , 27, 773-781		17
262	In vivo and in vitro effects of vortioxetine on molecules associated with neuroplasticity. <i>Journal of Psychopharmacology</i> , 2017 , 31, 365-376	4.6	8
261	Subchronic vortioxetine treatment -but not escitalopram- enhances pyramidal neuron activity in the rat prefrontal cortex. 2017 , 113, 148-155		17
260	Efficacy, safety, and tolerability of vortioxetine in the treatment of mood disorders. 2017 , 27, S863-S864		
259	Depressed Caucasians with Met allele of BDNF Val66Met polymorphism have more deleterious metabolic changes after antidepressant treatment than Val/Val. 2017 , 27, S864		
258	Preclinical Models for Assessment of Antidepressant Abuse Potential. 2017 , 9, 241-250		
257	Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram. 2017 , 8, 764		8
256	Laminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex. 2017 , 11, 87		54
255	The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 2913-2919	3.1	13
254	New drugs in psychiatry: focus on new pharmacological targets. 2017 , 6, 397		17
253	Antidepressants and Sleep?. 2017 ,		
252	Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. 2017 , 18, 56		6
251	Sexual Dysfunction, Depression and Antidepressants: A Translational Approach. 2017 ,		
250	Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. 2018 , 101, 72-79		14
249	A Critical Role of Mitochondria in BDNF-Associated Synaptic Plasticity After One-Week Vortioxetine Treatment. 2018 , 21, 603-615		11
248	The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT receptor expressing interneurons: An in vitro study in rat hippocampus slices. 2018 , 1689, 1-11		14
247	Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. 2018 , 82, 332-338		11

246	Reprint of: Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats. 2018 , 82, 339-342	2
245	A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. 2018 , 21, 97-107	61
244	The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. 2018 , 229, 421-428	31
243	A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. 2018 , 21, 442-447	1
242	Acetylcholinesterase inhibitors in treatment-resistant psychotic depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2018 , 8, 59-61	4-9 4
241	The 5-HT receptor - a potential target for antidepressant treatment. 2018 , 235, 1317-1334	31
240	Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. 2018 , 23, 1127-1133	34
239	Prefrontal cortex executive processes affected by stress in health and disease. 2018 , 85, 161-179	43
238	Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. 2018 , 175, 113-124	30
237	Acute effects of vortioxetine and duloxetine on resting-state functional connectivity in the awake rat. 2018 , 128, 379-387	8
236	Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. 2018 , 72, 64-72	21
235	Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. 2018 , 72, 103-115	12
234	Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. 2018 , 28, 445-456	46
233	Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. 2018 , 57, 673-686	56
232	Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. 2018 , 34, 593-600	9
231	When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity. <i>Therapeutic Advances in Psychopharmacology</i> , 2018 , 8, 63-70	4-9 11
230	NLX-112, a highly selective 5-HT receptor agonist: Effects on body temperature and plasma corticosterone levels in rats. 2018 , 165, 56-62	3
229	The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. 2018 , 227, 803-809	33

228	Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. 2018 , 227, 787-794	22
227	Vortioxetine overdose in a suicidal attempt: A case report. 2018 , 97, e10788	2
226	BDNF-Related Imbalance of Copine 6 and Synaptic Plasticity Markers Couples With Depression-Like Behavior and Immune Activation in CUMS Rats. 2018 , 12, 731	25
225	Perspectives on the Management of Vascular Depression. 2018 , 175, 1169-1175	4
224	Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. 2018 , 14, 1744806918808987	16
223	Vortioxetine Differentially Modulates MK-801-Induced Changes in Visual Signal Detection Task Performance and Locomotor Activity. 2018 , 9, 1024	1
222	Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT Receptor. 2018 , 94, 1421-1434	7
221	Pathophysiology and Medical Management of Hypoactive Sexual Desire Disorder. 2018 , 59-100	6
220	New Antidepressant Medication: Benefits Versus Adverse Effects. 2018 ,	
219	Other Antidepressants. 2019 , 250, 325-355	9
218	Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction. 2018 , 225-249	
217	Sexual Dysfunctions in Mentally Ill Patients. 2018 ,	1
216	Structure-Activity Relationships and Therapeutic Potentials of 5-HT Receptor Ligands: An Update. 2018 , 61, 8475-8503	27
215	Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). 2018 , 34, 1975-1984	8
214	Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. 2018 , 142, 1-7	52
213	Vortioxetine and Early Drug Development Considerations at the Interface of R&D. 2018 , 125-144	
212	Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. 2018 , 9, 162	14
211	Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. 2018 , 9, 204	5

210	Efficacy of vortioxetine on the physical symptoms of major depressive disorder. <i>Journal of Psychopharmacology</i> , 2018 , 32, 1086-1097	4.6	7
209	A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice. 2018 , 97, 120-130		36
208	Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report. 2018 , 28, 107-109		2
207	Serotonin receptors in depression and anxiety: Insights from animal studies. <i>Life Sciences</i> , 2018 , 210, 106-124	6.8	82
206	The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. 2018 , 141, 214-222		11
205	5-HT1A receptor ligands and their therapeutic applications: review of new patents. 2018 , 28, 679-689		17
204	Hypomanic switch during vortioxetine treatment: a case report. 2019 , 29, 114-116		7
203	Pros and cons of 5-HT receptor antagonists in neuropsychiatric diseases. 2019 , 118, 109301		2
202	Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT receptor ligands. 2019 , 180, 383-397		6
201	Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by A β Oligomers in Mice: A Key Role of Transforming Growth Factor- β . 2019 , 10, 693		33
200	Antidepressants and Sexual Dysfunctions: a Translational Perspective. 2019 , 11, 156-166		6
199	5-HT Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. 2019 , 71, 383-412		39
198	Serotonin and sexual behavior. 2019 , 117-132		3
197	Translational Approaches for Antidepressant Drug Development. 2019 , 29, 93-101		
196	Monoaminergic system and depression. 2019 , 377, 107-113		47
195	New Somatic Treatments for Child and Adolescent Depression. 2019 , 6, 380-400		1
194	Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR Titr3/J Mice. 2019 , 10, 4319-4327		7
193	Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. 2019 , 16, 1638-1649		15

192	Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors. 2019 , 120, 109408		8
191	Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect. 2019 , 183, 111736		10
190	Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT receptor ligands. 2019 , 166, 144-158		9
189	A one-pot metal-free protocol for the synthesis of chalcogenated furans from 1,4-enediones and thiols. 2019 , 17, 982-991		10
188	Cognitive impairment in depression: recent advances and novel treatments. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 1249-1258	3.1	73
187	Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. 2019 , 44, 1706-1713		3
186	Cognitive dysfunction in major depression: From assessment to novel therapies. <i>Pharmacology & Therapeutics</i> , 2019 , 202, 53-71	13.9	21
185	Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. 2019 , 236, 3183-3195		6
184	Continuous flow production in the final step of vortioxetine synthesis. Piperazine ring formation on a flow platform with a focus on productivity and scalability. 2019 , 9, 101-113		8
183	Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. 2019 , 250, 114-122		14
182	Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2019 , 33, 511-521	4.6	10
181	Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. 2019 , 24, 616-627		17
180	Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. 2019 , 250, 35-42		17
179	Molecular aspects of depression: A review from neurobiology to treatment. 2019 , 851, 99-121		42
178	Investigations on the Solubility of Vortioxetine Based on X-ray Structural Data and Crystal Contacts. 2019 , 9, 536		1
177	Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. 2019 , 10, 771		21
176	Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT Receptor with 5-HT Receptor Inhibition in Rats. 2019 , 20,		15
175	Meige Syndrome Related to Vortioxetine in 2 Sisters: Case Reports. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 679-681	1.7	1

174	Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. 2019 , 34, 153-160	7
173	The effectiveness and cost-effectiveness of e-health interventions for depression and anxiety in primary care: A systematic review and meta-analysis. 2019 , 245, 728-743	37
172	Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications. 2019 , 33, 17-29	6
171	Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. 2019 , 14, 81-89	38
170	Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON □ COCHRANE CORNER. 2019 , 25, 3-6	
169	SMIP004: A compound with antidepressant-like activities in mouse models. 2019 , 843, 260-267	4
168	Efficacy of vortioxetine in working patients with generalized anxiety disorder. 2019 , 24, 249-257	4
167	Rigor and reproducibility in rodent behavioral research. 2019 , 165, 106780	33
166	Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. 2020 , 27, 3830-3876	18
165	Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. 2020 , 25, 352-362	2
164	Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. 2020 , 36, 117-124	4
163	Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure. 2020 , 181, 113098	10
162	Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. 2020 , 1138, 121955	3
161	Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings - A Randomized, Crossover Trial in Healthy Males. 2020 , 424, 172-181	5
160	Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study. 2020 , 62, e94-e101	5
159	Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. 2020 , 263, 258-266	6
158	The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. 2020 , 34, 1133-1147	14
157	Vortioxetine induces apoptosis and autophagy of gastric cancer AGS cells via the PI3K/AKT pathway. 2020 , 10, 2157-2165	3

156	Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats. 2020 , 178, 108238	3
155	Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. 2020 , 1-9	2
154	Psychiatric Drug Discovery and Development. 2020 , 35-68	1
153	Can Pharmacological Augmentation of Cognitive Training Remediate Age-Related Cognitive Decline?. 2020 , 177, 485-487	0
152	Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. 2020 , 103, 109975	8
151	Central 5-HT receptors and their function; present and future. 2020 , 177, 108155	36
150	Vortioxetine improves rapid eye movement sleep behavior disorder: A case report. 2020 , 99, e21003	2
149	Identification and characterization of forced degradation products of vortioxetine by LC/MS/MS and NMR. 2020 , 188, 113442	2
148	A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. 2020 , 266, 173-181	2
147	Recent advances with 5-HT modulators for neuropsychiatric and gastrointestinal disorders. 2020 , 40, 1593-1678	12
146	Revisiting the behavioral genetics of serotonin: relevance to anxiety and depression. 2020 , 665-709	4
145	Vortioxetine administration attenuates cognitive and synaptic deficits in 5BAD mice. 2020 , 237, 1233-1243	6
144	Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial. 2020 , 177, 548-555	17
143	Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. 2021 , 24, 314-321	1
142	The rat hippocampal gliovascular system following one week vortioxetine and fluoxetine. 2021 , 42, 45-56	1
141	Potential antidepressant-like effect of piperazine derivative LQFM212 in mice: Role of monoaminergic pathway and brain-derived neurotrophic factor. 2021 , 401, 113066	2
140	Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. 2021 , 283, 472-479	14
139	Role of central serotonin and noradrenaline interactions in the antidepressants' action: Electrophysiological and neurochemical evidence. 2021 , 259, 7-81	3

138	Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. <i>Therapeutic Advances in Psychopharmacology</i> , 2021 , 11, 20451253211034320	4.9	2
137	Binding and activation of serotonergic G-protein coupled receptors by the multimodal antidepressant vortioxetine.		
136	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 172-179	1.7	1
135	Vortioxetine Prevents Lipopolysaccharide-Induced Memory Impairment Without Inhibiting the Initial Inflammatory Cascade. 2020 , 11, 603979		1
134	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 575-585	3.1	11
133	Vortioxetine increases absence-like seizures in WAG/Rij rats but decreases penicillin- and pentylenetetrazole-induced seizures in Wistar rats. 2021 , 116, 107797		3
132	Donepezil and Bynuclein Constipation: A 48 Month Follow-Up. 2021 , 1-7		0
131	Vortioxetine attenuates the effects of early-life stress on depression-like behaviors and monoamine transporters in female mice. 2021 , 186, 108468		2
130	Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. 2021 , 12, 635502		3
129	Risks Associated with Vortioxetine in the Established Therapeutic Indication. 2021 , 19, 711-717		
128	Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. 2021 , 285, 112-119		4
127	Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task. 2021 , 11, 9113		1
126	Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine. 2021 , 12, 641491		4
125	5-HT Serotonergic, β Adrenergic and Opioidergic Receptors Mediate the Analgesic Efficacy of Vortioxetine in Mice. 2021 , 26,		1
124	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. 2021 , 22, 561-628		3
123	Depression and Pain: use of antidepressant. 2021 ,		3
122	Synthesis and Antinociceptive Effect of Some Thiazole-Piperazine Derivatives: Involvement of Opioidergic System in the Activity. 2021 , 26,		0
121	Vortioxetine Improved Depressive State In Parkinson's Disease. 2021 , 13, e15750		

120	Vortioxetine improves cognition in mild cognitive impairment. 2021 , 36, 279-287		1
119	Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology. <i>Journal of Psychopharmacology</i> , 2021 , 2698811211032475	4.6	4
118	Vortioxetine Derivatives with Amino Acid as Promoiety: Synthesis, Activity, Stability and Preliminary Pharmacokinetic Study. 2021 , 110, 3011-3019		1
117	5-HT Receptors and the Development of New Antidepressants. 2021 , 22,		7
116	A Novel 5-HT Receptor Agonist of Herbal Compounds and One of the Therapeutic Uses for Alzheimer's Disease. 2021 , 12, 735876		0
115	Vortioxetine mitigates neuronal damage by restricting PERK/eIF2 β /ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. <i>Life Sciences</i> , 2021 , 283, 119865	6.8	0
114	A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). 2021 , 37, 2163-2173		4
113	Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. 2021 , 294, 924-931		2
112	Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. 2021 , 22,		13
111	Cognitive effects of vortioxetine in older adults: a systematic review.. <i>Therapeutic Advances in Psychopharmacology</i> , 2021 , 11, 20451253211026796	4.9	1
110	Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. 2017 , 27, 192-203		14
109	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. 2021 , 73, 310-520		48
108	Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder. 2017 , 39, 86		8
107	An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective. 2020 , 18, 168-187		13
106	Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. 2019 , 16, 50-58		10
105	Pharmacological treatment of cognitive deficits in nondementing mental health disorders?. 2019 , 21, 301-308		16
104	Donepezil and Bynuclein Constipation: A 36 Month Follow-Up. 2019 , 1-7		1
103	Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. 2021 , 1-26		1

102	Research Progress of the Antidepressants Targeting the Monoamine Receptors and Glutamate System. 2016 , 05, 38-44	
101	Substrates of Human CYP2D6. 2016 , 139-288	
100	Vortioxetine: a review of new antidepressant. 2016 , 17, 31-32	9
99	Some issues of antidepressant efficacy and tolerability relevant for routine clinical practice. 2016 , 17, 48-52	1
98	Medication for Sleep Problems in Posttraumatic Stress Disorder. 2018 , 325-348	2
97	The Antidepressants and the Metabolic Syndrome. 2018 , 91, 89-98	
96	Depressive and Anxiety Disorders. 2020 , 497-521	0
95	Depression and dementia: differentiation and comorbidity. 2020 , 12, 100-106	1
94	Pharmaceutical Salt Hydrates of Vortioxetine with Maleic Acid and Fumaric Acid: Crystal Structures, Characterisation and Solubility Performance. 2021 , 131847	1
93	Contemporary approaches to correction of cognitive impairment in endogenous depression. 2020 , 82-93	
92	A Real-World Chart Review Study of Monotherapy and Adjunctive Vortioxetine in Clinical Practice. 2021 , 14, 92-94	0
91	Efficacy and Tolerability of Vortioxetine in Patients with Major Depressive Disorder: A Clinical Perspective from 33 Indian Cases. 2021 , 14, 57-61	
90	Design strategies, chemistry and therapeutic insights of multi-target directed ligands as antidepressant agents. 2021 ,	1
89	Recovery of Visual Scotomas by Vortioxetine in a Patient with Symptomatic Occipital Lobe Epilepsy. 2018 , 21, 88-90	1
88	Vortioxetine as an analgesic in preclinical inflammatory pain models: Mechanism of action. 2021 ,	1
87	The impact of HTR1A and HTR1B methylation combined with stress/genotype on early antidepressant efficacy. 2021 ,	1
86	The potential for adverse effects in fish exposed to antidepressants in the aquatic environment. 2021 ,	6
85	Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 3735-3741	1

84	The Older Patient with Psychiatric Illness. 2022 , 169-197	
83	What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials.. 2022 ,	0
82	5-HT3Rs Maintain Hippocampal LTP in a CB1R-GABA -Dependent Manner for Spatial Memory.. 2022 ,	
81	The dual 5-HT3 and 5-HT6 receptor antagonist FPPQ normalizes phencyclidine-induced disruption of brain oscillatory activity in rats.. 2022 ,	0
80	Strategies for the detection, removal and elimination of antidepressants. 1-32	1
79	A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.. 2022 , 1-25	0
78	Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports.. 2022 , 45, 145	1
77	Diagnostic conversion from unipolar to bipolar affective disorder: a population-based study.. 2022 ,	0
76	Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson's disease via targeting TLR-2 mediated neuroinflammation.. 2022 , 208, 108977	0
75	Antidepressants, Sexual Behavior, and Translational Models for Male Sexual Dysfunction: Development of Animal Models, Pharmacology, and Genetics. 2022 , 451-515	0
74	Cognition and serotonin in Parkinson's disease.. 2022 , 269, 373-403	0
73	In vivo electrophysiological study of the targeting of 5-HT receptor-expressing cortical interneurons by the multimodal antidepressant, vortioxetine.. 2022 ,	
72	Vortioxetine 5, 10, and 20 mg Significantly Reduces the Risk of Relapse Compared With Placebo in Patients With Remitted Major Depressive Disorder: The RESET Study.. 2022 , 303, 123-123	0
71	Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention. 2021 , 55,	5
70	PET as a Translational Tool in Drug Development for Neuroscience Compounds.. 2022 ,	0
69	Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.. <i>Neuropsychiatric Disease and Treatment</i> , 2022 , 18, 363-373	3.1 0
68	Binding and Activation of Serotonergic G-Protein Coupled Receptors by the Multimodal Antidepressant Vortioxetine.. 2022 ,	
67	Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management.. 2022 ,	

66	Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations.. 2022,	0
65	Development of the Validated Stability-Indicating Method for the Determination of Vortioxetine in Bulk and Pharmaceutical Formulation by HPLC-DAD, Stress Degradation Kinetics Studies and Detection of Degradation Products by LC-ESI-QTOF-MS.. 2022, 27,	1
64	Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.. 2022, 13, 824831	2
63	Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants.. 2022, 1	2
62	Jumping From Fragment To Drug Via Smart Scaffolds.. 2022,	0
61	Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.. 2021, 1-18	2
60	Treatment induced Mood Switching in Affective Disorders.. 2021, 1-50	1
59	Modern Antidepressants in the Treatment of Mental Disorders in Post-COVID Conditions. 2021, 692-698	
58	Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD).. <i>Neuropsychiatric Disease and Treatment</i> , 2022, 18, 867-879	1
57	Data_Sheet_1.pdf. 2018,	
56	Data_Sheet_1.DOCX. 2018,	
55	Image_1.TIF. 2018,	
54	Image_2.TIF. 2018,	
53	Table_1.DOCX. 2018,	
52	Table_2.DOCX. 2018,	
51	Table_3.DOCX. 2018,	
50	Table_4.DOCX. 2018,	
49	Table_5.DOCX. 2018,	

48	Vortioxetine Induced Hypomania: A Case Presentation and Review of the Literature.. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022 , 20, 394-397	3.4	0
47	New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.. <i>Current Topics in Behavioral Neurosciences</i> , 2022 , 1	3.4	0
46	Gastrointestinal Hemorrhage After Antidepressant Drug Use: A Case Report.. <i>Journal of Clinical Psychopharmacology</i> , 2022 , 42, 333-335	1.7	1
45	Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.. <i>Journal of Psychopharmacology</i> , 2022 , 2698811221090627 ²	4.6	0
44	A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.. <i>Neuropsychiatric Disease and Treatment</i> , 2022 , 18, 965-976	3.1	0
43	Effect of aerobic exercise as a treatment on type 2 diabetes mellitus with depression-like behavior zebrafish.. <i>Life Sciences</i> , 2022 , 300, 120578	6.8	1
42	Supporting Individuals with Mental Health and/or Addictions Issues Through Patient Navigation: A Scoping Review. <i>Community Mental Health Journal</i> ,	2.1	0
41	Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant. <i>Biomedicines</i> , 2022 , 10, 1318	4.8	0
40	Antidepressants for depressed patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of short-term randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 139, 104731	9	0
39	Mechanisms of action and clinical effects of vortioxetine. <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2022 , 122, 84	0.4	0
38	Vortioxetine as adjunctive therapy in the treatment of schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2022 , 12, 204512532211100	4.9	0
37	Prevalence of Sexual Dysfunction in Women With Depression: Need for Psychosexual Health Promotion Approach. <i>Journal of Psychosexual Health</i> , 263183182211078	0.9	0
36	Donepezil and 5-HT _{2A} Receptor Constipation: A 60 Month Follow-Up. 2022 , 1-8		
35	Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study. Volume 18, 1665-1677		0
34	The Implication of 5-HT Receptor Family Members in Aggression, Depression and Suicide: Similarity and Difference. 2022 , 23, 8814		2
33	Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects. 2022 , 22,		0
32	The microbiota-gut-brain axis and its modulation in the therapy of depression: Comparison of efficacy of conventional drugs and traditional Chinese medicine approaches. 2022 , 183, 106372		1
31	Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study. Volume 18, 1963-1974		0

- 30 Magnesium Potentiates the Vortioxetine Effects on Physical Performances and Biological Changes in Exercise-Induced Stress in Rats. **2022**, 58, 1363 ○
- 29 Vortioxetine liposomes as a novel alternative to improve drug stability under stress conditions: toxicity studies and evaluation of antidepressant-like effect. ○
- 28 Vortioxetine treatment decreases cocaine-induced locomotor sensitization in rats. **2022**, 257, 113989 1
- 27 Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson Disease Patients with Major Depression: An Open-Label Prospective Study. **2022**, 12, 1466 ○
- 26 The clinical utility of newer antidepressant agents: Understanding the role in management of MDD. **2022**, 12, 309-319 ○
- 25 Transition Metal Catalysed C-S Cross-Coupling Reactions at Room Temperature.. **2022**, 7, ○
- 24 Spectroscopic, reactivity analysis and docking studies of 3-(adamantan-1-yl)-4-(4-fluorophenyl)-1-[(4-phenylpiperazin-1-yl)methyl]-4,5-dihydro-1H-1,2,4-triazole-5-thione: DFT and MD simulations. **2023**, 1274, 134418 ○
- 23 Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study. 026988112211324 ○
- 22 The motivation and energy inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study. **2022**, ○
- 21 Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research. **2022**, 12, 1 ○
- 20 Fluoxetine increased adult neurogenesis is mediated by 5-HT₃ receptor. **2023**, 795, 137027 ○
- 19 Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study. ○
- 18 The resolution of the Expert Council on the Diagnosis, Treatment, and Prevention of Symptoms of Depression in Outpatients with New Coronavirus Infection. **2022**, 56, 112-123 ○
- 17 Combined cognitive training and vortioxetine mitigates age-related declines in functional brain network integrity. **2023**, ○
- 16 A novel strategy for designing the magic shotguns for distantly related target pairs. ○
- 15 Agonistic properties of a series of psychotropic drugs at 5-HT_{1A} receptors in rat and human brain membranes determined by [³⁵S]GTP binding assay. ○
- 14 Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study. 13, ○
- 13 Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates. **2023**, 100064 ○

- 12 Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea. 14, ○
- 11 Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter. **2023**, 66, 371-383 ○
- 10 Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. **2023**, ○
- 9 Augmentation of Cognitive Training With Vortioxetine Opens New Avenues for Targeting Age-Related Changes in Brain Connectivity. **2023**, ○
- 8 Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders. **2023**, 13, 318 ○
- 7 Rhodium-catalyzed selenylation and sulfenylation of quinoxalines in water. **2023**, 13, 6191-6198 ○
- 6 Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea. 14, ○
- 5 Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia. **2023**, 12, 837 ○
- 4 Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies. **2023**, 39, 613-619 ○
- 3 Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges. **2023**, 24, 5270 ○
- 2 Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression. 1-17 ○
- 1 Cognitive Decline and Its Associated Factors in Patients with Major Depressive Disorder. **2023**, 11, 950 ○